CPD content overview:
|
Current
Strategies for the Long-term Assessment, Monitoring, and Management of Cystic
Fibrosis Patients Treated with CFTR Modulator Therapy
|
 |
|
The
content for this activity is based on the satellite symposium, “Current
Strategies for the Long-term Assessment, Monitoring, and Management for Cystic
Fibrosis Patients Treated with CFTR Modulator Therapy” that was presented at the
39th European Cystic Fibrosis Society Conference in Basel, Switzerland on June
10, 2016. The emergence of novel targeted agents, that directly correct CFTR
loss function alleles, has created new treatment opportunities for patients with
cystic fibrosis with advanced disease. Knowledge of the role of these agents in
the clinical setting is quickly evolving and will require physicians stay
acquainted with the latest data as well as evidence-based treatment guidelines
in order to achieve optimized cystic fibrosis patient care.
|
